Disclaimer:
This infographic is not a validated clinical decision aid. This information is provided without any representations, conditions, or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility for any aspect
of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions:
http://www.bmj.com/company/legal-information/
Current evidence for covid-19 treatments
Visual summary of living systematic review and network meta-analysis
© 2020 BMJ Publishing Group Ltd.
Interactive
Lorem ipsum dolor sit amet, consectetuer adipiscing
elit, sed diam nonummy nibh euismod tincidunt ut
laoreet dolore magna aliquam erat volutpat. Ut wisi
enim ad minim veniam, quis nostrud exerci tation
ullamcorper suscipit lobortis nisl ut aliquip ex ea
commodo consequat. Duis autem vel eum iriure
dolor in hendrerit in vulputate velit esse molestie
consequat, vel illum dolore eu feugiat nulla facilisis
at vero eros et accumsan et iusto odio dignissim qui
blandit praesent luptatum zzril delenit augue
blandit praesent luptatum zzril delenit augue
Lorem ipsum dolor sit amet,
consectetuer adipiscing elit, sed diam
nonummy nibh euismod tincidunt ut
laoreet dolore magna aliquam erat
volutpat. Ut wisi enim ad minim
veniam, quis nostrud exerci tation
ullamcorper suscipit lobortis nisl ut
aliquip ex ea commodo consequat.
Duis autem vel eum iriure dolor in
hendrerit in vulputate velit esse
molestie consequat, vel illum dolore
eu feugiat nulla facilisis at vero eros et
accumsan et iusto odio dignissim qui
blandit praesent luptatum zzril delenit
augue
Last updated
18 Jun 2020
Evidence quality displayed:
High
Moderate
Low
Very low
View past versions
Published
Preprints
Upcoming
Trials
Participants
Included in review
To be included
in next update
Certainty in
how beneficial
a treatment is
Higher
Lower
How to read
this diagram
Mortality
Data sources
28
28
28
4928
4928
4928
23 Trials
1423 Participants
Peer reviewed studies published in medical journals
Draft of research paper shared publicly, but not peer-reviewed yet
Research published while preparing the most recent
update, which will be included in the next update
Standard care
Most effective
Most effective
Most effective
Most effective
28
Diammonium
glycyrrhizinate +
lopinavir-ritonavir
Antiviral
Classification:
Moderately promising
Total trials
including
intervention
Total
participants
4928
Diammonium
glycyrrhizinate +
lopinavir-ritonavir
Diammonium
glycyrrhizinate +
lopinavir-ritonavir
versus
Risk difference
Days
1.2
Risk difference
per 1000 people
999
Evidence quality (GRADE score)
Moderate
Network estimate
Direct comparison
Remdesivir
Because the evidence for many comparisons and outcomes is very
limited, some of the results obtained in the analysis are implausible.
The effect estimates obtained are extremely large, and the evidence
was classified as very low certainty
To differentiate between plausible and implausible very low
certainty evidence, we do not show the effect estimates and the
grey “direction of effect” circle when the estimates are highly
implausible. Results that are highly implausible should not be used
to inform practice.
When selecting links, the numerical values will not be shown for
implausible results, and will be replaced by a warning symbol.
Implausible results
Relative efficacy
≤ 5 times higher
Ratio-based
outcomes
Absolute time to
event outcomes
Relative efficacy
> 5 times higher
Relative difference
in efficacy ≤ 10 days
Relative difference
in efficacy > 10 days
This diagram summarises how treatments compare to each other and the certainty of the evidence available
Interacting with the diagram
Different outcomes
can be selected in
the drop down
menu to the top
left of the diagram
Comparisons can be
filtered by certainty
of evidence using
checkboxes to the
bottom left
Individual treatments and
comparisons can be selected
to highlight connections and
view numerical values
for efficacy
The width of the links show the
certainty of the evidence, according to
the GRADE rating for that comparison
Very low
Low
Moderate
High
The position of the smaller grey circles between
the treatments shows their relative efficacy
Not different
Each of the coloured circles
around the edge of the diagram
represents one treatment . They
are grouped by how promising
the treatment appears, given
the current evidence and its
certainty
Left treatment two or
more times as beneficial
as the right treatment
Right treatment two or
more times as beneficial
as the left treatment
Not different
Left treatment improves
time to event by five days
or more
Right treatment
improves time to event
by five days or more
Ratio based outcomes
Absolute time-to-event outcomes
Evidence quality
DRAFT